18:22 , May 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Nerve damage Mouse studies suggest agonizing ESR2 could help treat enteric nerve damage. In a mouse model of chemical-induced damage to the ileal myenteric plexus, a subcutaneous ESR2 agonist tool compound decreased the neuron-depleted...
07:00 , Oct 31, 2011 |  BC Week In Review  |  Company News

Ausio, Marshall Edwards deal

Marshall Edwards granted Ausio exclusive, worldwide rights to develop and commercialize isoflavone metabolite equol for non-cancer indications. Marshall Edwards is eligible for royalties and a royalty-free license to undisclosed manufacturing-related IP from Ausio. Terms were...
08:00 , Feb 14, 2011 |  BC Week In Review  |  Clinical News

S-equol: Phase I data

Data from a pair of double-blind, placebo-controlled, U.S. Phase I trials in healthy volunteers showed that oral AUS-131 was well tolerated with no significant treatment-related adverse events reported. In the first study, 61 subjects received...